Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. APGE
6. DFTX
7. GOOGL
8. KR
9. MSTR
10. HOOD

Go back to Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Merck & Co. (NYSE: MRK) Delayed: 115.09 +1.22 (1.07%)
Previous Close $113.87    52 Week High $65.46 
Open $113.97    52 Week Low $47.97 
Day High $115.16    P/E 78.29 
Day Low $113.00    EPS $1.47 
Volume 3,070,928